Vivo Bio Tech (BOM:511509) Cash-to-Debt : 0.02 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Vivo Bio Tech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vivo Bio Tech's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.02.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vivo Bio Tech couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Vivo Bio Tech's Cash-to-Debt or its related term are showing as below:

BOM:511509' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 2.31
Current: 0.02

During the past 13 years, Vivo Bio Tech's highest Cash to Debt Ratio was 2.31. The lowest was 0.02. And the median was 0.04.

BOM:511509's Cash-to-Debt is ranked worse than
98.36% of 1524 companies
in the Biotechnology industry
Industry Median: 6.225 vs BOM:511509: 0.02

Vivo Bio Tech Cash-to-Debt Historical Data

The historical data trend for Vivo Bio Tech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vivo Bio Tech Cash-to-Debt Chart

Vivo Bio Tech Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.04

0.03

0.02

Vivo Bio Tech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.02	N/A	0.03	N/A	0.02

Competitive Comparison of Vivo Bio Tech's Cash-to-Debt

For the Biotechnology subindustry, Vivo Bio Tech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivo Bio Tech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vivo Bio Tech's Cash-to-Debt falls into.

Vivo Bio Tech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vivo Bio Tech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.896	/	(312.767	+	417.871)
	=	0.02

Vivo Bio Tech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.896	/	(312.767	+	417.871)
	=	0.02

Vivo Bio Tech (BOM:511509) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vivo Bio Tech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vivo Bio Tech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivo Bio Tech (BOM:511509) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivo Bio Tech Ltd (BOM:511509) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 8-2-672/ 5 and 6, Road Number 1, 3rd Floor, Ilyas Mohammed Khan Estate, Banjara hills, Hyderabad, TG, IND, 500034

Website

http://www.vivobio.com

Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.

Vivo Bio Tech (BOM:511509) Headlines

No Headlines